Editor’s Letter

Editor’s Letter

Welcome to the 17th edition of HD Insights, timed for release at the 21st International Congress of Parkinson Disease and Movement Disorders in Vancouver, BC. We continue our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers. 

In this edition, we continue our focus on gene-targeting therapies for HD, and explore other developments in HD therapeutics. We begin with an article about the recent FDA approval of Teva’s deutetrabenazine (AUSTEDO™). Dr. Lise Munsie investigates recent publications on gene-targeted therapies in her “Research Round-up” series. We talk with Dr. Beverly Davidson about her many contributions to gene-silencing therapies for HD and other neurological diseases, and explore the latest in game-changing gene-silencing therapies with Dr. Amber Southwell. Dr. Nicholas Caron reports on the highlights of the CHDI meeting in Malta in April. Dr. Irina Kerkis describes the latest in HD research in Brazil, especially research on stem-cell-based therapies developed with Dr. Monica Haddad. Ms. Jennifer Simpson and Dr. George Yohrling from the HDSA describe the findings of their survey exploring the preferences and priorities of the HD community for HD research, a highlight from the Journal of Huntington’s Disease. Finally, we continue to update the HD community on upcoming, ongoing, and recently completed clinical trials.

This edition marks the last edition of Meredith Achey’s tenure as Deputy Editor. Through boundless energy and dedication, Meredith has helped shape every aspect of HD Insights for the last four years. Only the increasing demands of medical school took her away from her work at HD Insights, and we wish her all the best. We welcome incoming Deputy Editor Sara LaJeunesse to the HD Insights team. Sara comes to us with a wealth of writing, editing, and publishing experience, and we are excited to continue to grow with her leadership.

If you or your colleagues would like a free electronic subscription to HD Insights, please visit www.HDInsights.org and complete the subscription form. We welcome your job postings, scholarship announcements, and other opportunities you would like to share with the HD community. If you have an opportunity you would like to share with nearly 3,000 HD researchers and clinicians, or would like to give us feedback, comments, or contributions, please email us at editor@hdinsights.org. Thank you. 

Editor’s Letter

Welcome to the 16th edition of HD Insights, timed for release at the beginning of the first Pan-American Parkinson’s Disease and Movement Disorders Congress in Miami, FL. Now in our sixth year, we continue our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers. This 16th edition marks the beginning of a year-long focus on game-changing genetic therapies preparing to enter human trials, along with the continuation of our clinical trials update, Research Round-Ups, and the conversations with HD clinicians, scientists, and industry representatives that we have brought you since 2011.

We begin our first 2017 edition with a look back at the major developments in HD clinical research from 2016. We then bring you some of the most highly cited research of 2015, with articles from Dr. Zhenyu Yue and Dr. Margaret Pearce exploring the roles of autophagy and phagocytosis in HD pathology. Dr. Lise Munsie continues her excellent Research Round-Up series. We sit down with Dr. Pavlina Konstantinova of uniQure, a company working to create a one-time gene-silencing treatment for HD patients using micro RNA. Ms. Marleen van Walsem and colleagues describe their work evaluating the impact of assistive technology for cognition in improving HD patients’ quality of life, a highlight from the Journal of Huntington’s Disease. Ms. Molly Elson describes the highlights of the 2016 HSG Annual Meeting for those who could not attend. Finally, we continue to update the HD community on upcoming, ongoing, and recently completed clinical trials. We have streamlined our trial listing to add a “Pipeline” to this edition, allowing us more space to explore those compounds and treatments currently in preclinical as well as clinical development. We welcome your thoughts and comments on this new feature.

HD Insights is dedicated to bringing together ideas and people in the HD community to advance HD research. This edition, we are announcing the search for a new Deputy Editor, to lead the periodical into the future as Meredith Achey steps away to focus on her medical training. We also welcome your job postings, scholarship announcements, and other opportunities you would like to share with the HD community. If you have an opportunity you would like to share with nearly 3000 HD researchers and clinicians, please let us know at editor@hdinsights.org.

If you or your colleagues would like a free electronic subscription to HD Insights, please visit www.HDInsights.org and complete the subscription form. We truly appreciate your comments, suggestions, and contributions. If you would like to get in touch, please email editor@hdinsights.org. Thank you.

Editor’s Letter

Editor's letter featured imageWelcome to the 15th edition of HD Insights, released at the 2016 Huntington Study Group (HSG) Annual Meeting in Nashville, TN. We are proud to be celebrating five years of pursuing our mission to promote, disseminate, and facilitate HD research with content that is valuable and informative to the global community of HD researchers. This 15th edition marks the third year of our Insights of the Year competition, the second of our Meet the Next Generation of HD researchers feature, and the continuation of our updates on HD clinical trials, compounds in development, and research from around the world. We are grateful to our sponsors, our readers, and our authors for their contributions towards our ongoing mission.
This year, our Editorial Board and last year’s Insights of the Year winners nominated 17 articles as the most influential developments in HD research from July 2015-July 2016. All 17 explore fascinating and promising discoveries and advancements in our understanding of HD and in our attempts to develop treatments. The three winners, selected by the Editorial Board and previous awardees, will be presenting their work at a panel session at the HSG meeting on November 2. Also at this year’s meeting, the 2016 HDSA Human Biology Fellows awarded scholarships to attend HSG and the two 2016 Shoulson Scholars, featured in our “Meet the Next Generation” series, will be presenting their research and connecting with new and veteran investigators and researchers from around the world. This edition also brings you an update from Dr. Kimberly Kegel-Gleason on the promise and opportunities in the use of induced pluripotent stem cells in HD research, a highlight from the Journal of Huntington’s Disease. Dr. Joseph Ochaba shares his work exploring potential therapeutic targeting of PIAS1 to diminish neurodegeneration. We sit down with WAVE Life Sciences, a new biotechnology company using proprietary techniques to produce stereopure nucleic acid therapies for HD and other rare diseases, and introduce you to their new compounds. Finally, we continue to update the HD community on upcoming, ongoing, and recently completed clinical trials.
HD Insights is dedicated to creating connections and bringing together ideas and people in the HD community to advance HD research. This edition features job opportunities both for those in training and at a later stage in their careers, in academia and in industry. If you have an opportunity you would like to share with nearly 3000 HD researchers and clinicians, please let us know at editor@hdinsights.org.
Your comments, suggestions, and contributions are invaluable to us. If you would like to get in touch, please email editor@hdinsights.org. If you or your colleagues would like a free electronic subscription to HD Insights, please visit www.HDInsights.org and complete the subscription form. Thank you for all that you do.
-Ray Dorsey, Editor, HD Insights
disclosures: dr. dorsey receives grant support from prana biotechnology, teva, roche, biomarin, raptor pharmaceuticals and the huntington study group.

Editor’s Letter

 Ray DorseyWelcome to the fourteenth edition of HD Insights, released at the beginning of the 20th International Congress of Parkinson Disease and Movement Disorders in Berlin, Germany. We are grateful to you, our readers, and to our sponsors, for your continued support of our mission to promote, disseminate, and facilitate research in HD.

This edition examines the promise and potential pitfalls of evaluating interventions in patients at-risk for HD. In an interview with Dr. Diana Rosas, we discuss clinical trial designs pioneered by the PRECREST study, which allow at-risk individuals to participate in therapeutic trials without the difficult burden of genetic testing. Dr. Nancy Downing, featured in HD Insights, Vol. 12 as a “Next Generation” HD Scholar, describes her work evaluating lifestyle-based interventions to improve quality of life and potentially delay onset of HD, while Drs. Govinda Poudel and Nellie Georgiou-Karistianis detail their recently published analysis of data from the IMAGE-HD study evaluating imaging markers of neuropsychiatric symptoms in individuals at-risk for HD. Dr. Lise Munsie brings you the highlights of this year’s CHDI meeting, and continues to synthesize the latest HD research in her Research Round-Up feature. As always, we continue to update you on ongoing and recently concluded clinical trials in HD.

This edition of HD Insights also introduces efforts to further connect and encourage HD research collaborations. Dr. Helen Budworth, also featured in HD Insights, Vol. 12 as a “Next Generation” HD Scholar, shares funding opportunities available through the California Institute for Regenerative Medicine. Additionally, through our new Job Opportunities section, we hope to provide another resource for our colleagues in academia and industry to connect to one another and share opportunities. If you have an opportunity you would like featured in HD Insights, please send us an email at editor@hdinsights.org. As always, we welcome your suggestions, comments, and feedback, and invite you to subscribe electronically by visiting our new website. Thank you for your continued support.

Ray Dorsey, Editor in Chief

    HD InsightsTM

Ray Dorsey’s disclosures: Dr. Dorsey receives grant support from Prana Biotechnology, Teva, Roche, Biomarin, Raptor Pharmaceuticals and the Huntington Study Group.

Editor’s Letter

rayD_100x100Welcome to the thirteenth edition of HD Insights, timed for release at the beginning of the 11th Annual CHDI HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate, and facilitate research in HD, and grateful to our subscribers, our editorial board, and our sponsors for their generous support of the periodical. 

For our first edition of 2016, HD Insights introduces a new layout and a renewed emphasis on bringing you the latest in preclinical and clinical HD research. We profile Ionis Pharmaceuticals’ antisense oligonucleotide IONIS-HTTRx, currently in a Phase I/IIa trial. We interview the team of scientists and physicians responsible for the drug’s development, and explore Ionis’ partnership with Roche Pharmaceuticals in an interview with Dr. Scott Schobel. We highlight a selection of highly cited original research articles from 2014, including new insights into the role of astrocytes in HD pathophysiology, a mutation commonly responsible for HD phenocopy syndromes, and the importance of autophagosome abnormalities in HD. Dr. Alpar Lazar describes his work with Dr. Roger Barker, characterizing the emergence of sleep disturbances in prodromal HD patients. Our colleagues at the Journal of Huntington’s Disease continue to advance HD research through excellent scholarship. We selected one article from their recent edition and invited the authors to share their work on the new Genetic Modifiers of Motor Onset Age database. Dr. Lise Munsie reprises her Research Round-Up, and joins our editorial team as a scientific content reviewer. Then, for those who were unable to attend HSG 2015, Shoulson Scholar Mr. George McNally summarizes the highlights of that meeting. Finally, we continue to provide an up-to-date status report on HD clinical trials and the development of novel therapies in the pipeline.

HD Insights relies on the support of those firms dedicated to advancing HD therapeutics to continue to bring you the latest on HD research. If you would like to become a supporter, or to submit an article, comment, or suggestion, please send us an email at editor@hdinsights.org. For a free electronic subscription, please send an email to subscribe@hdinsights.org. Thank you for your continued support.

Ray Dorsey, Editor in Chief

    HD InsightsTM

ray dorsey’s disclosures: Dr. Dorsey receives grant support from Prana Biotechnology, Teva, and the Huntington Study Group. He is a consultant to Teva and BioMarin.

Editor’s Letter

dorseyWelcome to the twelfth edition of HD Insights, released at the 2015 Huntington Study Group Annual Meeting and Ninth Annual HD Clinical Research Symposium. We are pleased to continue our mission to promote, disseminate, and facilitate research in HD. We thank our subscribers, our Editorial Board, our newest sponsors, Teva Pharmaceuticals and Raptor Pharmaceuticals, and our founding and longtime supporter, Lundbeck Inc., for their generous support of the periodical.

This edition highlights exciting current research and up-and-coming HD researchers. In our new “Meet the Next Generation” feature, we profile early- to mid-career investigators who have been recognized by the Huntington’s Disease Society of America and the HSG as investigators with promising futures in HD research. All six have been invited to attend the 2015 HSG Annual Meeting to present their work. With the second year of the Insights of the Year competition, we bring you nine of the most influential publications in HD from July 2014 to July 2015, identified by the winners of last year’s competition. Authors of the four most influential papers, selected by our Editorial Board and other researchers, will present their work in a special panel session at the HSG meeting. Dr. Maurice Zauderer, founder, president, and CEO of Vaccinex Inc., discusses his company and their monoclonal antibody VX15/2503, which has just entered Phase II trials in HD. For those who were unable to attend the 19th International Congress of Parkinson’s Disease and Movement Disorders in San Diego, CA this year, we summarize the HD-related highlights of that meeting. Finally, we continue to provide an up-to-date status report on HD clinical trials.

HD Insights strives to provide relevant, interesting, and useful information to the global HD research community in academia and industry. We will continue to introduce new features and new explorations in the coming year, and welcome your suggestions and submissions. If you would like to become a supporter, or submit an article, comment, or suggestion, please send us an email at editor@hdinsights.org. For a free electronic subscription, please send an email to subscribe@hdinsights.org. Thank you for your continued support.
– – RAY DORSEY, EDITOR I N CHIEF

Editorial Board Members
Ray Dorsey, MD — Editor, University of Rochester
Donald Kennedy, PhD — Stanford University
Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute
Rodrigo Osorio — Agrupación Chilena de Huntington
Bernard Ravina, MD — Voyager Therapeutics
Ralf Reilmann, MD, PhD — George Huntington Institute
Sarah Tabrizi, MBChB, PhD — University College London
Leslie Thompson, PhD — University of California Irvine

Contributors
Meredith A. Achey, BM
Chen Chang, PhD
Yijuang Chern, PhD
Janelle Drouin-Ouellet, PhD
Marta Fernández-Nogales, PhD
Chien-Hsiang Huang, PhD
Joshua L. Plotkin, PhD
Steven G. Potkin, MD
Amber L. Southwell, PhD
Zhiqun Tan, PhD
Romina Vuono, PhD
Edward J. Wild, PhD
X. William Yang, PhD

Publication Staff
Meredith A. Achey — Deputy Editor
Robin Taylor — Production Editor
Martin Holmes — Technical Editor
David Kolko — Distribution Specialist

Huntington Study Group
Shari Kinel, JD — HSG Executive Director
Liz McCarthy, BA — HSG Director, Special Programs
Heather Hare, BA — HSG Director, Communications & Outreach
Stevan Ramirez, MBA — HSG Director, Finance & Operations
Kristin Strazdins — HSG Accounting and Office Manager

HD INSIGHTS (TM)
DISCLOSURES: DR . DORSEY RECEIVES GRANT SUPPORT FROM PRANA BIOTECHNOLOGY, TEVA, AND THE HUNTINGTON STUDY GROUP.

 

Editor’s Letter

Welcome to the 11th edition of HD Insights. We are pleased to continue our mission to promote, disseminate, and facilitate research in Huntington disease. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 2800 subscribers for their continuing support.

This issue investigates potential therapeutic strategies for HD treatment and provides a detailed update on disease-modifying strategies set to enter clinical trials in the upcoming year. We discuss Teva’s recent acquisition of Auspex following the promising results of FIRST-HD released earlier this year. We bring you an interview with former FDA attorney Mr. Frank Sasinowski, on his work with the 1983 Orphan Drug Act, his hopes for orphan drug development, and his advice for researchers and companies working to develop new therapies for rare diseases. Dr. Shaun Sanders describes the therapeutic potential of increasing palmitoylation of mHTT, thereby decreasing its toxicity and aggregation within HD patients. Dr. Dagmar Ehrnhoefer details several studies showing that wild-type HTT plays an important role in myristoylation and autophagy, and promotes the clearance of misfolded mHTT. Dr. Lise Munsie summarizes ongoing HD research and Dr. Daniel Zielonka discusses promising diseasemodifying strategies aimed at lowering HTT. Dr. Francesca Cicchetti shares the highlights of February’s CHDI meeting. Finally, we continue to provide an up-to-date status report on ongoing and recently concluded HD clinical trials.

The HD Insights team continues to rely on the support of firms dedicated to developing novel treatments to support our efforts to reach and educate the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org. We welcome new contributors, suggestions for topics, and ideas about how we can better serve you. If you or someone you know would like to share their ideas with over 2800 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org . Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org.

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR. DORSEY RECEIVES GRANT SUPPORT FROM AUSPEX PHARMACEUTICALS, THE HUNTINGTON STUDY GROUP, AND PRANA BIOTECHNOLOGY.


 

Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupación Chilena de Huntington

Bernard Ravina, MD — Voyager Therapeutics

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Director of Programs & Communications

Kristin Strazdins — HSG Accounting and Office Manager

Contributors

Francesca Cicchetti, PhD

Dagmar E. Ehrnhoefer, PhD

Ryan E. Korn, BA

Lise Munsie, PhD

Shaun S. Sanders, PhD

Daniel C. Zielonka, MD, PhD

Publication Staff

Meredith A. Achey, BM — Deputy Editor

Ryan E. Korn, BA — Associate Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

David Kolko — Distribution Specialist

Editor’s Letter

Welcome to the 10th edition of HD Insights, timed for the beginning of CHDI’s 10th Annual HD Therapeutics Conference. We are pleased to continue our mission to promote, disseminate and facilitate research in Huntington disease. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 2600 subscribers for their continuing support.

This edition explores several promising areas of current HD research. We discuss the positive results of Auspex Pharmaceuticals’ First-HD trial, which give the HD community hope of a second FDA-approved treatment for HD. We interview Dr. Francesca Cicchetti, whose groundbreaking research was featured in the Insights of the Year competition last fall, and bring you her thoughts on advances in our current understanding of HD and the future of HD research and therapies. Dr. Lise Munsie provides a “round-up” of current basic science and clinical research in HD. Our editorial team examines the use of laquinimod in neurodegenerative disease, which has led to the ongoing LEGATO-HD Phase 2 trial, and brings you the highlights of HSG 2014. Finally, we continue to provide an up-to-date status report on ongoing and recently concluded HD clinical trials.

The HD Insights team continues to rely on the support of firms dedicated to developing novel treatments to support our efforts to reach and educate the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org . We welcome new contributors, suggestions for topics, and ideas about how we can better serve you. If you or someone you know would like to share their ideas with over 2600 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org . Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org.

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR. DORSEY RECEIVES GRANT SUPPORT FROM AUSPEX PHARMACEUTICALS, THE HUNTINGTON STUDY GROUP, AND PRANA BIOTECHNOLOGY.


Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupación Chilena de Huntington

Bernard Ravina, MD — Voyager Therapeutics

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Director of Programs & Communications

Donna Moszkowicz — HSG Event Planner

Kristin Strazdins — HSG Accounting and Office Manager

Contributors

Meredith A. Achey, BM

Ryan E. Korn, BA

Lise Munsie, PhD

Publication Staff

Meredith A. Achey, BM — Deputy Editor

Ryan E. Korn, BA — Associate Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

David Kolko — Distribution Specialist

Editor’s Letter

Welcome to the 9th edition of HD Insights. We are grateful to the Huntington Study Group (HSG), our sponsors, and our over 2,500 subscribers for their continuing support of our mission.

In this special edition, we feature Dr. Ira Shoulson, founder and leader of the HSG from 1996 to 2014. Dr. Shoulson’s leadership and vision have been powerful forces for HD research for forty years. HD Insights also brings you the nominees and winners of the first Insights of the Year competition. The HD Insights staff and expert HD researchers nominated eleven papers published between July 2013 and July 2014 in HD basic science, clinical research, and biomarkers research, for consideration by our Editorial Board. The Board voted on the papers to select the most influential paper in each category. As a result, Drs. Francesca Cicchetti, Chris S. Tang, and X. William Yang will be presenting their winning research in a special panel session at the HSG meeting. In addition to these highlights, we bring you an interview with Ms. Julie Smith, President and CEO (designate) of Raptor Pharmaceuticals, who tells of her hopes for the company’s ongoing clinical trial with cysteamine bitartrate in HD. Our interview with Ms. Smith was edited by our newest team member, Associate Editor Ryan Korn, whose contributions we will feature in the coming year.

HD Insights relies on the support of firms dedicated to developing novel treatments to bring the latest research to the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org. We welcome new contributors, suggestions for topics, and ideas about how we can better serve you. If you or someone you know would like to share their ideas with over 2,500 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org. Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR. DORSEY RECEIVES GRANT SUPPORT FROM PRANA BIOTECHNOLOGY AND AUSPEX PHARMACEUTICALS


Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupación Chilena de Huntington

Bernard Ravina, MD — Voyager Therapeutics

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Administrative Manager

Contributors

Meredith A. Achey, BM

Francesca Cicchetti, PhD

Laura E. Clemens

Christina Colletta, BA

Nellie Georgiou-Karistianis, PhD

Flaviano Giogini, PhD

Victoria Gonzalez, MD, PhD

Steven M. Hersch, MD, PhD

Erik K. H. Jansson

Robert Mason, PhD

Miriam Moscovitch-Lopatin, PhD, PMP

Lise Munsie, PhD

Diana Rosas, MD Chris C. Tang, MD, PhD

William Yang, MD, PhD

Publication Staff

Meredith A. Achey, BM — Deputy Editor

Ryan Korn, BA — Associate Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

David Kolko — Distribution Specialist

Editor’s Letter

Welcome to the 8th edition of HD Insights, released at the 8th European Huntington Disease Network Plenary Meeting in Barcelona, Spain. We are grateful to the Huntington Study Group (HSG), our sponsors, and our more than 1500 subscribers for their continuing support of our mission. HD Insights relies on the support of firms dedicated to developing novel treatments to bring the latest research to the international HD research community. If you are interested in becoming a supporter, please contact me at editor@hdinsights.org .

This issue explores the variety of animal models currently used to support ongoing discovery in HD pathology and drug development. Dr. Mahmoud Pouladi provides an overview of HD animal models based on his exhaustive review published last September in Nature Reviews Neuroscience. Dr. Hoa Nguyen describes his research at the University of Tuebingen, developing a BACHD rat model and evaluating the cholesterol analog olesoxime in vitro and in vivo, and his clinical work with predictive genetic testing. The HD highlights of June’s MDS Congress in Stockholm, Sweden give a glimpse into the future of HD trials, while Dr. Christiane Dascher-Nadel describes the latest European initiative to advance stem cell research for HD through the Repair-HD project.

We are also excited to announce the first Insights of the Year competition, in which our frequent contributor Dr. Lise Munsie has nominated eleven publications from the last year in HD basic science, clinical, and biomarkers research for consideration by our Editorial Board. The board will vote for the most influential paper in each category, and the authors of the chosen papers will be invited to present in a special panel session at November’s HSG meeting in Minneapolis, Minnesota.

We welcome new contributors, suggestions for topics, and suggestions for how we can better serve you. If you or someone you know have ideas that you would like to share with 1500 HD researchers and clinicians around the world, please contact me at editor@hdinsights.org .

Finally, subscription to HD Insights is always free: simply send us an email at subscribe@hdinsights.org

Dorsey_feat

 

 

 

 

 

 

 

 

Ray Dorsey, MD

Editor, HD INSIGHTSTM

HD DISCLOSURES: DR. DORSEY RECEIVES GRANT SUPPORT FROM LUNDBECK AND PRANA BIOTECHNOLOGY AND CONSULT S FOR AMGEN, LUNDBECK, AND MEDTRONIC.


Editorial Board Members

Ray Dorsey, MD — Editor, University of Rochester

Donald Kennedy, PhD — Stanford University

Nobuyuki Nukina, MD, PhD — Riken Brain Science Institute

Rodrigo Osorio — Agrupación Chilena de Huntington

Bernard Ravina, MD — Voyager Therapeutics

Ralf Reilmann, MD, PhD — George Huntington Institute

Sarah Tabrizi, MBChB, PhD — University College London

Leslie Thompson, PhD — University of California Irvine

Huntington Study Group

Shari Kinel, JD — HSG Executive Director

Liz McCarthy, BA — HSG Administrative Manager

Contributors

Meredith A. Achey, BM

Christiane Dascher-Nadel, PhD

Stephen Dunnett, PhD, DSc

Lise Munsie, PhD

Mahmoud A. Pouladi, PhD

Anne Rosser, PhD, FRCP

Publication Staff

Meredith A. Achey, BM — Deputy Editor

Robin Taylor — Production Editor

Martin Holmes — Technical Editor

David Kolko — Distribution Specialist

For more information on HD Insights, or to receive a free subscription, please visit us at www.hdinsights.org  or email us at editor@hdinsights.org .

1 2